• Sihuan Pharmaceutical Holdings Group Ltd., of Hong Kong, said the China Food and Drug Administration accepted its application for clinical trial approval of pirotinib. In preclinical studies, the second-generation inhibitor, aimed at the treatment of lung and breast cancer, demonstrated beneficial profiles in pharmacology, pharmacokinetics and toxicology.